| 2501 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
47 |
| 2502 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
29 |
| 2503 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
66 |
| 2504 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
68 |
| 2505 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
40 |
| 2506 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
56 |
| 2507 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
69 |
| 2508 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
59 |
| 2509 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
56 |
| 2510 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
68 |
| 2511 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
66 |
| 2512 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
63 |
| 2513 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
64 |
| 2514 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
64 |
| 2515 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
63 |
| 2516 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
65 |
| 2517 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
68 |
| 2518 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
44 |
| 2519 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
66 |
| 2520 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
48 |
| 2521 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
45 |
| 2522 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
67 |
| 2523 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
69 |
| 2524 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
72 |
| 2525 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
53 |
| 2526 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
71 |
| 2527 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
66 |
| 2528 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
57 |
| 2529 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
74 |
| 2530 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
72 |
| 2531 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome Lb High Risk
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
58 |
| 2532 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome With Multilineage Dysplasia
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
68 |
| 2533 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome/Acute Myelogenous Leukemia
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
42 |
| 2534 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome-Eb1
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
48 |
| 2535 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndromes (MDS)
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
73 |
| 2536 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndromes (MDS)
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
76 |
| 2537 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndromes (MDS)
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
70 |
| 2538 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndromes (MDS)
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
5 |
| 2539 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
65 |
| 2540 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
56 |
| 2541 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
70 |
| 2542 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
69 |
| 2543 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
61 |
| 2544 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
70 |
| 2545 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
68 |
| 2546 |
Apheresis |
Allogeneic
|
Myelofibrosis Myeloid Metaplasia
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
50 |
| 2547 |
Apheresis |
Allogeneic
|
Myelofibrosis Myeloid Metaplasia
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
54 |
| 2548 |
Apheresis |
Allogeneic
|
Myelofibrosis Myeloid Metaplasia
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
60 |
| 2549 |
Apheresis |
Allogeneic
|
Myeloma Multiplex
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
63 |
| 2550 |
Apheresis |
Autologous
|
No Data
|
Hematology
|
2023
|
Standard Therapy
|
Germany
|
69 |
| 2551 |
Apheresis |
Autologous
|
No Data
|
Hematology
|
2023
|
Standard Therapy
|
Germany
|
53 |
| 2552 |
Apheresis |
Allogeneic
|
No Data
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
50 |
| 2553 |
Apheresis |
Allogeneic
|
No Data
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
23 |
| 2554 |
Apheresis |
Allogeneic
|
No Data
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
39 |
| 2555 |
Apheresis |
Allogeneic
|
No Data
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
2 |
| 2556 |
Apheresis |
Allogeneic
|
No Data
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
52 |
| 2557 |
Apheresis |
Allogeneic
|
No Data
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
61 |
| 2558 |
Apheresis |
Autologous
|
No Data
|
Hematology
|
2023
|
Standard Therapy
|
Germany
|
60 |
| 2559 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
71 |
| 2560 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
44 |
| 2561 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
72 |
| 2562 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
66 |
| 2563 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
33 |
| 2564 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
42 |
| 2565 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
63 |
| 2566 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
19 |
| 2567 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
54 |
| 2568 |
Apheresis |
Autologous
|
Nonseminoma, Relapse
|
Hematology
|
2023
|
Standard Therapy
|
Germany
|
48 |
| 2569 |
Apheresis |
Allogeneic
|
Orofacial Myofunctional Disorders (OMDS), Primary Myelofibrosis (PMF)
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
69 |
| 2570 |
Apheresis |
Allogeneic
|
Osteomyelofibrosis
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
60 |
| 2571 |
Apheresis |
Allogeneic
|
Other Immune System
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
71 |
| 2572 |
Apheresis |
Allogeneic
|
Other Malignancy
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
49 |
| 2573 |
Apheresis |
Allogeneic
|
Other Myelofibrosis
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
56 |
| 2574 |
Apheresis |
Allogeneic
|
Other Non-Malignant Disease
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
70 |
| 2575 |
Apheresis |
Allogeneic
|
Paroxysmal Nocturnal Hemoglobinuria (Pnh)
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
36 |
| 2576 |
Apheresis |
Allogeneic
|
Peripheral T-Cell Lymphoma
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
47 |
| 2577 |
Apheresis |
Autologous
|
Plasma Cell Leukemia
|
Hematology
|
2023
|
Standard Therapy
|
Germany
|
70 |
| 2578 |
Apheresis |
Autologous
|
Plasma Cell Leukemia
|
Hematology
|
2023
|
Standard Therapy
|
Germany
|
56 |
| 2579 |
Apheresis |
Autologous
|
Plasmacytoma
|
Hematology
|
2023
|
Standard Therapy
|
Germany
|
63 |
| 2580 |
Apheresis |
Allogeneic
|
Post Therapeutic Myelodysplastic Syndrome /Acute Myelogenous Leukemia After Chronic Lymphocytic Leukemia
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
60 |
| 2581 |
Apheresis |
Allogeneic
|
Post–Polycythemia Vera Myelofibrosis
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
38 |
| 2582 |
Apheresis |
Allogeneic
|
Pra B-Cell Acute Lymphoblastic Leukemia
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
20 |
| 2583 |
Apheresis |
Allogeneic
|
Pre-B-Acute Lymphoblastic Leukemia
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
41 |
| 2584 |
Apheresis |
Allogeneic
|
Pre-B-Acute Lymphoblastic Leukemia
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
61 |
| 2585 |
Apheresis |
Allogeneic
|
Pre-B-Acute Myelogenous Leukemia
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
11 |
| 2586 |
Apheresis |
Autologous
|
Primary Central Nervous System Lymphoma
|
Hematology
|
2023
|
Standard Therapy
|
Germany
|
63 |
| 2587 |
Apheresis |
Autologous
|
Primary Central Nervous System Lymphoma
|
Hematology
|
2023
|
Standard Therapy
|
Germany
|
73 |
| 2588 |
Apheresis |
Allogeneic
|
Primary Myelofibrosis
|
Hematology
|
2023
|
Standard Therapy
|
Germany
|
70 |
| 2589 |
Apheresis |
Allogeneic
|
Primary Myelofibrosis
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
68 |
| 2590 |
Apheresis |
Allogeneic
|
Primary Myelofibrosis
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
68 |
| 2591 |
Apheresis |
Allogeneic
|
Primary Myelofibrosis
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
31 |
| 2592 |
Apheresis |
Allogeneic
|
Primary Myelofibrosis
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
63 |
| 2593 |
Apheresis |
Allogeneic
|
Primary Myelofibrosis
|
Hematology
|
2023
|
Standard Therapy
|
Germany
|
46 |
| 2594 |
Apheresis |
Allogeneic
|
Primary Myelofibrosis
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
68 |
| 2595 |
Apheresis |
Allogeneic
|
Relapsed B-Cell Acute Lymphoblastic Leukemia
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
11 |
| 2596 |
Apheresis |
Allogeneic
|
Secondary Acute Myeloid Leukemia
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
55 |
| 2597 |
Apheresis |
Allogeneic
|
Severe Aplastic Anemia
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
58 |
| 2598 |
Apheresis |
Allogeneic
|
Severe Aplastic Anemia
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
36 |
| 2599 |
Apheresis |
Allogeneic
|
Severe Aplastic Anemia
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
62 |
| 2600 |
Apheresis |
Allogeneic
|
Severe Aplastic Anemia
|
Hematology
|
2023
|
Standard Therapy
|
Poland
|
9 |